Miranza’s R&D&I teams are already working on the clinical trial of the VEMoS Project by collecting samples from 1,400 eyes at Miranza IOA and at Vissum Grupo Miranza, the centre where the system’s code is being processed, as well as at two European centres: Portugal (Centro Hospitalar e Universitário de Coimbra) and Denmark (Aarhus Universitetshospital).
Our ophthalmic all-in-one diagnostic devices (CSO´S MS39-AXL and Open Field Aberrometer) have arrived at our clinics to proceed with the clinical validation of the VEMoS project! This single device will provide the highest number of visual analysis tools (corneal and ocular wavefront and topography). The biometric data collected from the MS39-AXL will be used as